We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Relationship between saxagliptin use and left ventricular diastolic function assessed by cardiac MRI.
- Authors
Wong, Kathy C. K.; Ismail, Huda S.; Connelly, Kim A.; Verma, Subodh; Ng, Ming-Yen; Deva, Djeven P.; Yan, Andrew T.; Jimenez-Juan, Laura
- Abstract
Aims: Type 2 diabetes mellitus (T2DM) increases the risk of major cardiovascular events. In SAVOR-TIMI53 trial, the excess heart failure (HF) hospitalization among patients with T2DM in the saxagliptin group remains poorly understood. Our aim was to evaluate left ventricular (LV) diastolic function after 6 months of saxagliptin treatment using cardiac magnetic resonance imaging (CMR) in patients with T2DM. Methods: In this prospective study, 16 T2DM patients without HF were prescribed saxagliptin as part of routine guideline-directed management. CMR performed at baseline and 6 months after initiation of saxagliptin treatment were evaluated in a blinded fashion. We assessed LV diastolic function by measuring LV peak filling rate with correction for end-diastolic volume (PFR/LVEDV), time to peak filling rate with correction for cardiac cycle (TPF/RR), and early diastolic strain rate parameters [global longitudinal diastolic strain rate (GLSR-E), global circumferential diastolic strain rate (GCSR-E)] by feature tracking (FT-CMR). Results: Among the 16 patients (mean age of 59.9, 69% males, mean hemoglobin A1c 8.3%, mean left ventricular ejection fraction 57%), mean PFR was 314 ± 108 ml/s at baseline and did not change over 6 months (− 2.7, 95% CI − 35.6, 30.2, p = 0.86). There were also no significant changes in other diastolic parameters including PFR/EDV, TPF, TPF/RR, and GLSR-E and GCSR-E (all p > 0.50). Conclusion: In T2DM patients without HF receiving saxagliptin over 6 months, there were no significant subclinical changes in LV diastolic function as assessed by CMR.
- Subjects
CARDIAC magnetic resonance imaging; GLOBAL longitudinal strain; LEFT ventricular hypertrophy; TYPE 2 diabetes; HEART beat; VENTRICULAR ejection fraction
- Publication
Acta Diabetologica, 2024, Vol 61, Issue 1, p91
- ISSN
0940-5429
- Publication type
Article
- DOI
10.1007/s00592-023-02177-x